BRAF and familial atrioventricular septal defect: We show that vemurafenib is an effective and well tolerated therapy for the treatment of intra-axial CNS infiltrative lesions in ECD patients who are positive for the p. V600E BRAF mutation, suggesting a neoplastic origin of the disease.